Hyphen Pharma - SAC Capital 2023-05-25: Beyond The Shores

• Hyphens Pharma (SGX:1J5), established in 1998, is Singapore’s leading specialty pharmaceutical and consumer healthcare group with a diverse footprint in ASEAN countries.
• Hyphens Pharma holds exclusive licenses and main distributorship with top pharmaceutical companies globally, mainly from Europe and the United States. They also build a strong franchise by means of in-licensing and R&D collaborations with reputable research institutions in Singapore.
• - Read this at SGinvestors.io -
• - Read this at SGinvestors.io -
• Hyphens Pharma products are selling in the premium market while Novem are targeting mostly the public sector. Prior to Novem acquisition, ~42% of sales are from the government. With the Healthier SG scheme, the public sector will grow at a faster pace, benefitting the Hyphens Pharma from the acquisition where ~60% of Novem sales are to government hospitals and polyclinics.

Hyphens Pharma – Investment Thesis

Internationalization

• Read more at SGinvestors.io.

Yeo Peng Joon SAC Capital Research | Matthias Chan SAC Capital | https://www.saccapital.com.sg/ 2023-05-25 SGinvestors.io

---